Cardiology
RSSArticles
-
Asymptomatic Transmission of COVID-19 in Households
Efforts to control secondary transmission should be given to households and those contact groups where any case of secondary transmission has been identified.
-
Combined GIP/GLP-1 Agonist: Safe for Type 2 Diabetes Patients?
In the SURPASS-2 trial, tirzepatide showed noninferiority and superiority vs. semaglutide in decreasing A1c levels in patients with type 2 diabetes.
-
Progression of Coronary Calcium on Statin Treatment
In those treated with statins vs. those who were not, statins decreased plaque volume in plaques with little or no calcium (plaque regression) and increased calcium density without changes in plaque volume in calcified plaques (plaque stabilization).
-
First-Line Therapy for Hypertension
When comparing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARBs) to treat hypertension, researchers observed no difference in major cardiovascular events — but a better safety profile for ARBs.
-
Early Coronary Angiography in Out-of-Hospital Cardiac Arrest
In a trial of immediate vs. delayed coronary angiography for resuscitated out-of-hospital cardiac arrest, researchers found no significant benefit on 30-day mortality.
-
Slow, Steady, and Synchronized Wins the Race
In patients with atrial fibrillation and heart failure, definitive rate control via atrioventricular junction ablation and biventricular pacing resulted in a significant reduction in all-cause mortality vs. pharmacologic rate control.
-
Screen Older Heart Failure Patients for Transthyretin Cardiac Amyloidosis
A screening study of heart failure patients ≥ age 60 years, left ventricular ejection fraction ≥ 40%, and left ventricle wall thickness ≥ 12 mm revealed 6.3% prevalence of transthyretin cardiac amyloidosis, a highly treatable disease.
-
Is This Ventricular Tachycardia?
The ECG in the figure was obtained from an elderly man with chest pain and shortness of breath. Is the rhythm ventricular tachycardia?
-
Insulin Glargine-yfgn Injection (Semglee)
-
Anticoagulation Plus Antiplatelet Therapy in Chronic Atherosclerosis
An analysis of the COMPASS trial for the secondary endpoint of mortality showed the combination of low-dose rivaroxaban and aspirin significantly lowered the all-cause mortality rate vs. low-dose aspirin alone.